Continuous glucose monitoring: a sweet deal for paediatric type 1 diabetics
Children diagnosed with type 1 diabetes mellitus (T1DM) are at particular risk for long-term complications, including diabetic retinopathy, neuropathy, and nephropathy. Over the last few decades, clinical advancements in glucose monitoring and methods of insulin delivery have improved quality of life in T1DM, making strict glycaemic control, which can reduce long-term complication risk, more achievable. The continuous glucose monitor (CGM) is a minimally invasive subcutaneous device, which assesses subcutaneous interstitial glucose levels at five-minute intervals. Used in conjunction with multiple daily insulin injections, or continuous subcutaneous insulin infusion via insulin pump, the CGM has been proven to enhance metabolic control, reducing HbA1c levels as well as time spent in hypoglycaemia. Furthermore, CGM allows for retrospective analysis of blood glucose trends by clinicians, leading to individualised and precise management strategies. However, limitations to its use include cost efficacy, sensor accuracy, and insertion site irritation. This review will discuss the potential benefits and limitations of CGM use in a paediatric population, and the recommendation that CGM be made available to any paediatric diabetic who requests its use.
CommentsThe original article is available at http://www.rcsismj.com/ Part of the RCSIsmj collection: https://doi.org/10.25419/rcsi.c.6775842.v1
Published CitationAtteih S. Continuous glucose monitoring: a sweet deal for paediatric type 1 diabetics. RCSIsmj. 2016;9(1):57-61
- Undergraduate Research
PublisherRCSI University of Medicine and Health Sciences
- Published Version (Version of Record)